Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) have been given an average recommendation of “Buy” by the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $18.50.
KPTI has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 12th. initiated coverage on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. They set a “buy” rating and a $23.00 price objective for the company. BidaskClub downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, October 18th.
Karyopharm Therapeutics (KPTI) traded up $0.01 during midday trading on Friday, hitting $10.01. 89,302 shares of the stock were exchanged, compared to its average volume of 164,674. Karyopharm Therapeutics has a 52 week low of $7.48 and a 52 week high of $14.63. The company has a market cap of $471.81, a P/E ratio of -3.78 and a beta of 4.09.
In other Karyopharm Therapeutics news, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total value of $103,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Christopher Brett Primiano sold 27,042 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total transaction of $277,991.76. Following the completion of the sale, the senior vice president now directly owns 11,381 shares of the company’s stock, valued at $116,996.68. The disclosure for this sale can be found here. Insiders sold 62,000 shares of company stock valued at $630,069 over the last three months. 14.71% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of KPTI. Schwab Charles Investment Management Inc. raised its stake in shares of Karyopharm Therapeutics by 34.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 116,036 shares of the company’s stock valued at $1,051,000 after acquiring an additional 29,522 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Karyopharm Therapeutics by 8.8% during the second quarter. Rhumbline Advisers now owns 74,812 shares of the company’s stock valued at $677,000 after acquiring an additional 6,025 shares during the last quarter. Swiss National Bank raised its stake in shares of Karyopharm Therapeutics by 39.2% during the second quarter. Swiss National Bank now owns 56,850 shares of the company’s stock valued at $514,000 after acquiring an additional 16,000 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Karyopharm Therapeutics by 31.9% during the second quarter. Alliancebernstein L.P. now owns 43,430 shares of the company’s stock valued at $393,000 after acquiring an additional 10,500 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Karyopharm Therapeutics by 2.6% during the second quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock valued at $3,904,000 after acquiring an additional 10,787 shares during the last quarter. 60.92% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc (KPTI) Given Average Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/20/karyopharm-therapeutics-inc-kpti-given-average-rating-of-buy-by-analysts.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.